StockData
EXELNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends January 1

EXELIXIS, INC.

Financials through Q2 FY2026, quarter ended Jul 3, 2026Last filing: 10-Q on Aug 5, 2026
$62.68+0.45 (+0.72%)

Close on Oct 19, 2026

Market cap
$16.28B
P/E (TTM)
19.7
Dividend yield
–

Earnings

Next report expected Nov 3, 2026, during market hours (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2026
Ended Jul 3, 2026
Aug 5, 2026During market hours$628.70M$0.82$0.91
Q1 FY2026
Ended Apr 3, 2026
May 5, 2026During market hours$610.80M$0.79$0.87
Q4 FY2025
Ended Jan 2, 2026
Jan 12, 2026During market hours–––
Q3 FY2025
Ended Oct 3, 2025
Nov 4, 2025During market hours$597.80M$0.69$0.78
Q2 FY2025
Ended Jul 4, 2025
Jul 28, 2025During market hours$568.30M$0.65$0.75
Q1 FY2025
Ended Apr 4, 2025
May 13, 2025During market hours$555.40M$0.55$0.62
Q4 FY2024
Ended Jan 3, 2025
Jan 13, 2025During market hours–––
Q3 FY2024
Ended Sep 27, 2024
Oct 29, 2024During market hours$539.50M$0.40$0.47
Q2 FY2024
Ended Jun 28, 2024
Aug 6, 2024During market hours–––
Q1 FY2024
Ended Mar 29, 2024
Apr 30, 2024During market hours–––
Q4 FY2023
Ended Dec 29, 2023
Jan 8, 2024Before market open–––

Company guidance

Outlook given with results on Aug 5, 2026, compared with the previous outlook

MeasurePeriodGuidancevs. prior
Cost of goods sold, % of net product revenuesfiscal year 20263.5% to 4.5%Lowered
Effective tax ratefiscal year 202621% to 23%Raised
Net product revenuesfiscal year 2026$2.30B to $2.35BRaised
Research and development expensesfiscal year 2026$825.00M to $875.00MLowered
Selling, general and administrative expensesfiscal year 2026$575.00M to $625.00MLowered
Total revenuesfiscal year 2026$2.50B to $2.55BRaised

Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.

Press releases

Announcements Exelixis filed with the SEC